Why the study?
Patients with drug-resistant epilepsy frequently experience adverse events from drug interactions on multiple antiseizure medications, necessitating consensus best practices to manage patients during cenobamate titration and limit tolerability issues.
Population
International Delphi panel of expert epileptologists experienced in the clinical use of cenobamate and other ASMs
Design
Modified Delphi consensus process
Authors
Loading...
Early AEs may reduce adherence in DRE; leaves open optimal polytherapy strategies pending higher-level trials.
An international Delphi panel provides consensus recommendations for initiating cenobamate in patients with drug-resistant epilepsy to optimize dosing and minimize adverse events.
Steinhoff et al. (2024) studied Drug-resistant epilepsy with focal-onset seizures. Cenobamate was evaluated on Consensus best practices for managing patients during and after cenobamate titration. Cenobamate initiation in patients with focal-onset seizures should include treatment response evaluation at the 100-mg dose and proactive down-titration of concomitant sodium channel blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: